Oncosexology
is a multidisciplinary field composed of physicians, nurses, psychologists, and other health care professionals focusing on sexual issues in patients with cancer. Although any cancer diagnosis or treatment can be associated with sexual dysfunction, pelvic malignancies (such as prostate, bladder, or colorectal cancer) have the highest rates of sexual dysfunction in men. This includes erectile dysfunction, testosterone deficiency, ejaculatory dysfunction, orgasmic dysfunction, sexual incontinence, and penile shortening. Testicular cancer and hematologic malignancies also have a significant impact on patients ’ sexual func...
Source: Urologic Clinics of North America - August 21, 2021 Category: Urology & Nephrology Authors: Carolyn A. Salter, John P. Mulhall Source Type: research
Is There a Role for Vascular Surgery in the Contemporary Management of Erectile Dysfunction?
Erectile dysfunction management is intended to restore capacity for penile erection. Although effective, none of the currently available treatments approved by the US Food and Drug Administration reverse erectile dysfunction pathophysiology. Penile arterial bypass surgery is intended to restore erectile function without the need for the chronic use of vasoactive medications or penile prosthesis placement. In select cases, venous ligation surgery may be beneficial, but this approach is not supported by the most recent guidelines on erectile dysfunction management. The lack of high-quality research surrounding penile vascula...
Source: Urologic Clinics of North America - August 21, 2021 Category: Urology & Nephrology Authors: Ricardo Munarriz, Nannan Thirumavalavan, Martin S. Gross Source Type: research
Energy-Based Therapies for Erectile Dysfunction
Energy-based therapies are novel treatments for erectile dysfunction that are thought to work by stimulation of tissue vasodilation, neoangiogenesis, and so forth. Low-intensity extracorporeal shock wave therapy (Li-ESWT) is the energy-based therapy with the most robust evidence basis demonstrating efficacy and safety. Among this evidence, randomized controlled trials (RCTs) evaluating Li-ESWT have largely been focused on responders to phosphodiesterase-5 inhibitors. Many of these RCTs have limitations including short follow-up durations, inconsistent protocols, and small sample sizes. Until more diverse patient population...
Source: Urologic Clinics of North America - August 12, 2021 Category: Urology & Nephrology Authors: Raghav Pai, Jesse Ory, Carlos Delgado, Ranjith Ramasamy Source Type: research
Prostate Cancer Genetics: Changing the Paradigm of Care
Our understanding the genomic landscape of prostate cancer has greatly expanded over the last few years. The Human Genome Project initiated by the NIH in 1990 and completed in 2003 accelerated the application of genetic testing in daily patient care for many diseases, including prostate cancer. We are increasingly learning how these genetic studies may inform all aspects of prostate cancer care from screening and diagnosis, through the treatment of early-stage disease, to life-threatening metastatic castration-resistant disease. (Source: Urologic Clinics of North America)
Source: Urologic Clinics of North America - June 29, 2021 Category: Urology & Nephrology Authors: Leonard G. Gomella, Veda N. Giri Tags: Preface Source Type: research
Prostate Cancer Genetics: The Urologic Research Promissory Note Is Being Cashed
In 2017, the Sidney Kimmel Cancer Center of Thomas Jefferson University held the First International Consensus Conference on The Role of Genetic Testing for Inherited Prostate Cancer Risk, which was organized by Leonard G. Gomella, Karen E. Knudsen, and Veda N. Giri.1 This was followed by the 2019 Philadelphia Prostate Cancer Consensus Program: Implementation of Genetic Testing for Prostate Cancer by the same group.2 These conferences, which were multidisciplinary and attended by national and international experts, were hugely successful. (Source: Urologic Clinics of North America)
Source: Urologic Clinics of North America - June 29, 2021 Category: Urology & Nephrology Authors: Kevin R. Loughlin Tags: Foreword Source Type: research
Prostate Cancer Genetics: Changing the Paradigm of Care
UROLOGIC CLINICS OF NORTH AMERICA (Source: Urologic Clinics of North America)
Source: Urologic Clinics of North America - June 29, 2021 Category: Urology & Nephrology Authors: Leonard G. Gomella, Veda N. Giri Source Type: research
Copyright
ELSEVIER (Source: Urologic Clinics of North America)
Source: Urologic Clinics of North America - June 29, 2021 Category: Urology & Nephrology Source Type: research
Contributors
KEVIN R. LOUGHLIN, MD, MBA (Source: Urologic Clinics of North America)
Source: Urologic Clinics of North America - June 29, 2021 Category: Urology & Nephrology Source Type: research
Contents
Kevin R. Loughlin (Source: Urologic Clinics of North America)
Source: Urologic Clinics of North America - June 29, 2021 Category: Urology & Nephrology Source Type: research
Forthcoming Issues
Sexual Dysfunction: A New Era (Source: Urologic Clinics of North America)
Source: Urologic Clinics of North America - June 29, 2021 Category: Urology & Nephrology Source Type: research
Clinical Multigene Testing for Prostate Cancer
Germline genetic testing for prostate cancer (PC) is increasingly important as the clinical utility of germline variants in this patient population is understood better. To better characterize the clinical landscape of germline testing in PC, published clinical cohorts of PC who underwent clinical germline genetic analysis at point of care are reviewed. Limitations and heterogeneity of these cohorts are highlighted and pathogenic results with established or potential clinical utility in PC noted. The need for additional germline genetic studies is underscored, because the number of PC patients studied lags greatly behind t...
Source: Urologic Clinics of North America - June 14, 2021 Category: Urology & Nephrology Authors: Tala Berro, Elizabeth Barrett, Saud H. AlDubayan Source Type: research
Genetic Counseling for Men with Prostate Cancer
This article provides an overview of the historical aspects of genetic counseling, discusses the components needed to provide proper genetic counseling, summarizes genes related to hereditary prostate cancer risk, and reviews genetic privacy and genetic discrimination concerns related to germline genetic testing. (Source: Urologic Clinics of North America)
Source: Urologic Clinics of North America - June 14, 2021 Category: Urology & Nephrology Authors: Colette Hyatt, Carey McDougall, Susan Miller-Samuel, Jessica Russo Source Type: research
Basic Science and Molecular Genetics of Prostate Cancer Aggressiveness
Androgen receptor function, tumor cell plasticity, loss of tumor suppressors, and defects in DNA repair genes affect aggressive features of prostate cancer. Prostate cancer development, progression, and aggressive behavior are often attributable to function of the androgen receptor. Tumor cell plasticity, neuroendocrine features, and loss of tumor suppressors lend aggressive behavior to prostate cancer cells. DNA repair defects have ramifications for prostate cancer cell behavior. (Source: Urologic Clinics of North America)
Source: Urologic Clinics of North America - June 14, 2021 Category: Urology & Nephrology Authors: Matthew J. Schiewer, Karen E. Knudsen Source Type: research
Prostate Cancer Predisposition
The identification and characterization of alterations in prostate cancer (PCa) –predisposing genes can help to inform screening strategies in undiagnosed men and treatment options in men in both the clinically localized and in the metastatic setting. This review provides an overview of the genetic basis underlying hereditary predisposition to PCa, the current role of genetic s and PCa risk assessment, and how genetic risk factors affect aggressiveness and lethality of PCa. (Source: Urologic Clinics of North America)
Source: Urologic Clinics of North America - June 11, 2021 Category: Urology & Nephrology Authors: Yasin Bhanji, William B. Isaacs, Jianfeng Xu, Kathleen A. Cooney Source Type: research
Genetic Testing Guidelines and Education of Health Care Providers Involved in Prostate Cancer Care
Germline testing for prostate cancer (PCA) is revolutionizing PCA care. Two PARP inhibitors are FDA approved for men with metastatic, castration-resistant disease after progression on first-line therapies. In the screening setting, genetic test results may inform initiation and screening strategies. For men with early-stage disease, literature is emerging on the possible role of germline testing in active surveillance discussions. As such, urologists and oncologists must gain working knowledge of the principles and practice of germline testing and hereditary cancer implications for responsible implementation. Here the auth...
Source: Urologic Clinics of North America - June 11, 2021 Category: Urology & Nephrology Authors: James Ryan Mark, Carey McDougall, Veda N. Giri Source Type: research
